Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laser Vision Centers

This article was originally published in The Gray Sheet

Executive Summary

Registration for a secondary offering of 1.72 mil. shares, including 720,000 shares being sold by current shareholders, is filed with the SEC. The St. Louis-based laser vision correction services firm says the proceeds will be used to purchase additional equipment, fund possible future strategic acquisitions, make payments on previous acquisitions, expand patient financing programs, and for working capital and general corporate purposes. The growing popularity of laser vision correction helped spur a third-quarter (ended Jan. 31) revenue increase of 122% to $14.1 mil. Net income of $2.2 mil. compares to a loss of nearly $1 mil. for the comparable quarter one year ago. A.G. Edwards & Sons and Prudential Securities are underwriters for the offering

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel